Sensitization to Api m 1, Api m 2, and Api m 4: association with safety of bee venom immunotherapy

Ruiz, Berta; Serrano, Pilar; Verdú, Miriam; Moreno‐Aguilar, Carmen

doi:10.1016/j.anai.2015.01.010

Cited by 28 publications

(22 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The third allergen studied, the synthetic peptide Api m 4, was detected in 47% of patients in group A; this rate is similar to that described in a recent study [9]. Api m 4 can be considered a major allergen in our population as it was recognized by 100% of patients in group A, again confirming the findings of a previous study [10]. Overall, these data suggest that phenotype A patients have a similar sensitization profile to that previously described, while phenotype B patients have a high rate of polysensitization.…”

Section: Clinical Changes Bvit Safetysupporting

confidence: 79%

“…A recent study reported a high prevalence of sensitization to Api m 4 among HBV-allergic patients who experienced SRs during induction of bVIT, suggesting an association between SRs and sensitization to Api m 4 [10]. Furthermore, allergenic extracts currently available for bVIT are standardized on the basis of their enzymatic activity and total protein content, with no consideration of individual components.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

IgE-Api m 4 Is Useful for Identifying a Particular Phenotype of Bee Venom Allergy

Ruiz¹,

Serrano²,

Moreno‐Aguilar³

2016

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

Background and Objective: Different clinical behaviors have been identified in patients allergic to bee venom. Compound-resolved diagnosis could be an appropriate tool for investigating these differences. The aims of this study were to analyze whether specific IgE to Api m 4 (sIgE-Api m 4) can identify a particular kind of bee venom allergy and to describe response to bee venom immunotherapy (bVIT). Methods: Prospective study of 31 patients allergic to bee venom who were assigned to phenotype group A (sIgE-Api m 4 <0.98 kU/L), treated with native aqueous (NA) extract, or phenotype group B (sIgE-Api m 4 ≥0.98 kU/L), treated with purified aqueous (PA) extract. Sex, age, cardiovascular risk, severity of preceding sting reaction, exposure to beekeeping, and immunological data (intradermal test, sIgE/ sIgG4-Apis-nApi m 1, and sIgE-rApi m 2-Api m 4 were analyzed. Systemic reactions (SRs) during bVIT build-up were analyzed. Immunological and sting challenge outcomes were evaluated in each group after 1 and 2 years of bVIT. Results: Phenotype B patients had more severe reactions (P=.049) and higher skin sensitivity (P=.011), baseline sIgE-Apis (P=.0004), sIgE-nApi m 1 (P=.0004), and sIgG4-Apis (P=.027) than phenotype A patients. Furthermore, 41% of patients in group B experienced SRs during the build-up phase with NA; the sting challenge success rate in this group was 82%. There were no significant reductions in serial intradermal test results, but an intense reduction in sIgE-nApi m 1 (P=.013) and sIgE-Api m 4 (P=.004) was observed after the first year of bVIT. Conclusion: Use of IgE-Api m 4 as the only discrimination criterion demonstrated differences in bee venom allergy. Further investigation with larger populations is necessary.

show abstract

Section: Clinical Changes Bvit Safetysupporting

confidence: 79%

Section: Introductionmentioning

confidence: 99%

IgE-Api m 4 Is Useful for Identifying a Particular Phenotype of Bee Venom Allergy

Ruiz¹,

Serrano²,

Moreno‐Aguilar³

2016

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

show abstract

“…It is considered a minor allergen, with a prevalence of sensitization ranging from 22.9% to 29% [8,11]. However, it was recently described as a major allergen in other populations [12].…”

Section: Systemic Reactions Caused By Venom Immunotherapymentioning

confidence: 99%

“…The peptide melittin (Api m 4) is considered to be an allergen with low prevalence [8,10]. However, its relevance has recently been demonstrated, and it has been proposed as a biomarker of poor tolerance in patients at the initial stages of immunotherapy [11]. Melittin also makes it possible to distinguish between 2 forms of allergy to bee venom [12].…”

Section: Latest Advances In the Molecular Diagnosis Of Insect Venom Amentioning

confidence: 99%

“…However, it was recently described as a major allergen in other populations [12]. Sensitization to Api m 4 has been proposed as a candidate biomarker of poor tolerance in patients at the initial stages of bee venom immunotherapy, even from very low specific IgE values, and was shown to discriminate between 2 different ways of being allergic to bee venom [8,11].…”

Section: Systemic Reactions Caused By Venom Immunotherapymentioning

confidence: 99%

See 1 more Smart Citation

Key Issues in Hymenoptera Venom Allergy: An Update

Alfaya

Soriano-Gomis

Mera

et al. 2017

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

In this review, the Hymenoptera Allergy Committee of the SEAIC analyzes the most recent scientific literature addressing problems related to the diagnosis of hymenoptera allergy and to management of venom immunotherapy. Molecular diagnosis and molecular risk profiles are the key areas addressed. The appearance of new species of hymenoptera that are potentially allergenic in Spain and the associated diagnostic and therapeutic problems are also described. Finally, we analyze the issue of mast cell activation syndrome closely related to hymenoptera allergy, which has become a new diagnostic challenge for allergists given its high prevalence in patients with venom anaphylaxis.

show abstract

Natural history of systemic reactions and risk factors in children and adults with Hymenoptera venom allergy

Antolín‐Amérigo¹,

Ruíz-León²,

Vega-Castro³

et al. 2020

Allergo J

View full text Add to dashboard Cite

Sensitization to Api m 1, Api m 2, and Api m 4: association with safety of bee venom immunotherapy

Cited by 28 publications

References 6 publications

IgE-Api m 4 Is Useful for Identifying a Particular Phenotype of Bee Venom Allergy

IgE-Api m 4 Is Useful for Identifying a Particular Phenotype of Bee Venom Allergy

Key Issues in Hymenoptera Venom Allergy: An Update

Natural history of systemic reactions and risk factors in children and adults with Hymenoptera venom allergy

Contact Info

Product

Resources

About